Skip to main content
Guttmacher Institute

Search

  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • Contact

Highlights

  • Reproductive Health Impact Study
  • Adding It Up
  • Abortion Worldwide
  • Guttmacher-Lancet Commission
  • US policy resources
  • State policy resources
  • International Perspectives on Sexual and Reproductive Health (1975–2020)
  • Perspectives on Sexual and Reproductive Health (1969–2020)

Reports

  • Global
  • United States

Articles

  • Global research
  • US research
  • Policy analysis
  • Guttmacher Policy Review
  • Opinion

Fact Sheets

  • Global
  • United States
  • US State Laws and Policies

Tools

  • Interactive Map: US Abortion Policies and Access After Roe
  • Family Planning Investment Impact Calculator
  • Monthly Abortion Provision Study Dashboard
  • State legislation tracker
  • Public-use data sets

Global

  • Abortion
  • Contraception
  • Pregnancy
  • Teens

US

  • Abortion
  • Contraception
  • Pregnancy
  • Teens

Our Work by Geography

  • Global
  • Africa
  • Asia
  • Europe
  • Latin America & the Caribbean
  • Northern America
  • Oceania

Who We Are

  • About
  • Staff
  • Board
  • Job opportunities
  • Newsletter
  • History
  • Contact
  • Conflict of Interest Policy

Media

  • Media office
  • News releases

Support Our Work

  • Make a gift today
  • Monthly Giving Circle
  • Ways to Give
  • Guttmacher Guardians
  • Guttmacher Legacy Circle
  • Financials
  • Impact Report 2025

Awards & Scholarships

  • Darroch Award
  • Richards Scholarship
  • Bixby Fellowship
Donate
Guttmacher Institute
Donate

Highlights

  • Reproductive Health Impact Study
  • Adding It Up
  • Abortion Worldwide
  • Guttmacher-Lancet Commission
  • US policy resources
  • State policy resources
  • International Perspectives on Sexual and Reproductive Health (1975–2020)
  • Perspectives on Sexual and Reproductive Health (1969–2020)

Reports

  • Global
  • United States

Articles

  • Global research
  • US research
  • Policy analysis
  • Guttmacher Policy Review
  • Opinion

Fact Sheets

  • Global
  • United States
  • US State Laws and Policies

Tools

  • Interactive Map: US Abortion Policies and Access After Roe
  • Family Planning Investment Impact Calculator
  • Monthly Abortion Provision Study Dashboard
  • State legislation tracker
  • Public-use data sets

Global

  • Abortion
  • Contraception
  • Pregnancy
  • Teens

US

  • Abortion
  • Contraception
  • Pregnancy
  • Teens

Our Work by Geography

  • Global
  • Africa
  • Asia
  • Europe
  • Latin America & the Caribbean
  • Northern America
  • Oceania

Who We Are

  • About
  • Staff
  • Board
  • Job opportunities
  • Newsletter
  • History
  • Contact
  • Conflict of Interest Policy

Media

  • Media office
  • News releases

Support Our Work

  • Make a gift today
  • Monthly Giving Circle
  • Ways to Give
  • Guttmacher Guardians
  • Guttmacher Legacy Circle
  • Financials
  • Impact Report 2025

Awards & Scholarships

  • Darroch Award
  • Richards Scholarship
  • Bixby Fellowship
Donate
  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • Contact
Video
November 25, 2025

Guttmacher expert Kelly Baden debunks anti-abortion myths

Kelly Baden (Vice President for Public Policy) debunks anti-abortion misinformation about mifepristone, affirming its decades-long safety record, global approval, and critical role in telehealth and self-managed abortion, while exposing politically motivated tactics that restrict access and fuel stigma. 

Video

Transcript: Medication abortion, especially mifepristone, has become the target of widespread misinformation. Let's separate some common myths from reality.

Mifepristone is one of the medications used in medication abortion in the US. The anti-abortion movement keeps making false claims about its safety, which has real policy implications that can make care harder to get.  

The truth is, mifepristone is a safe and effective medication backed by decades of research. It is approved in at least 100 countries and endorsed by leading medical authorities like the World Health Organization and the American College of Obstetricians and Gynecologists.  

Another area of anti-abortion misinformation is their exaggeration of potential complications by using shoddy science, but the research tells the real story. While symptoms like heavy bleeding and cramping are normal aspects of a medication abortion, serious adverse events are very rare and occur in well below one percent of cases. Of course, patient safety is paramount, but selective framing of long-established data as being new or alarming is a politically motivated tactic to create a culture of fear and stigma around abortion at a time when reproductive rights are already under attack.  

Additional myths, like those suggesting that medication abortion requires increased barriers to access, are deeply harmful. They get in the way of someone seeking or getting the abortion care they need. In reality, medication abortion has been proven safe for telehealth and self-managed abortion and in the deeply fractured US abortion access landscape, where 12 states are enforcing total abortion bans, these are critical pathways for people to get the care they need.  

Attacks on medication abortion aren't rooted in science. They're about political ideology. When we correct misinformation, we're not just setting the record straight. We're defending evidence-based medicine and protecting access to essential reproductive health care for all. 

Share

Guttmacher Institute

Center facts. Shape policy.
Advance sexual and reproductive rights.®

Donate Now
Newsletter Signup  Contact Us 
  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • Contact

Footer

  • Privacy Policy
  • Accessibility Statement
© 2026 Guttmacher Institute. The Guttmacher Institute is registered as a 501(c)(3) nonprofit organization under the tax identification number 13-2890727. Contributions are tax deductible to the fullest extent allowable.